The FDA expanded the approval of Moderna’s RSV vaccine, extending the license to include more adults and giving the company a welcome win.

Moderna said the Food and Drug Administration expanded its approval of the pharmaceutical company's respiratory syncytial virus vaccine, mResvia, to adults aged 18-59 at increased risk for the disease ...

The U.S. Food and Drug Administration on Thursday expanded the use of Moderna's respiratory syncytial virus vaccine to a ...

Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS ...

The Trump administration’s cancellation of $766 million in contracts to develop mRNA vaccines against potential pandemic flu ...

Health organizations urge insurers to keep covering vaccinations during pregnancy after Trump administration alters ...

Daniel Suárez se ha convertido en el guía turístico no oficial de todo lo relacionado con la Ciudad de México mientras NASCAR ...

After soaring to success in the early days of the COVID-19 pandemic, Moderna (NASDAQ: MRNA) experienced a reversal of fortune ...

US Health Secretary Robert F. Kennedy Jr.'s dismissal of a key panel that advises on immunizations policy is a significant ...

Moderna Inc. is in discussions with large drugmakers and financial firms to get funding for some late-stage vaccine trials as ...

The Food and Drug Administration (FDA) has approved Moderna’s next-generation mRNA COVID-19 vaccine mNexspike ®.

The Trump administration is waging war against mRNA vaccines despite President Donald Trump having called them the “gold standard” when his admin rolled out the COVID shots […] ...